Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;56(9):4625-9.
doi: 10.1128/AAC.00280-12. Epub 2012 Jun 11.

Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design

Affiliations

Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design

Kamilia Abdelraouf et al. Antimicrob Agents Chemother. 2012 Sep.

Abstract

The increasing prevalence of multidrug-resistant Gram-negative infections has led to renewed interest in the use of systemic polymyxin B. However, the nephrotoxic properties of polymyxin B are still poorly understood. The objective of this study was to characterize nephrotoxicity associated with polymyxin B, with an emphasis on examining the impact of dosing frequencies on the onset of nephrotoxicity. Sprague-Dawley rats were divided into two groups and administered the same total daily dose of polymyxin B subcutaneously but with different dosing frequencies (either 20 mg/kg of body weight every 24 h [q24h] or 5 mg/kg q6h). Drug concentrations in renal tissue were compared between the two groups at 24 h. Kidney tissues were harvested at 48 h and compared histologically. Serum creatinine was measured daily for up to 10 days, and nephrotoxicity was defined as a significant elevation in serum creatinine (≥2× baseline). Kaplan-Meier analysis was used to compare the onset of nephrotoxicity. Polymyxin B-induced nephrotoxicity manifested as elevation in serum creatinine and acute tubular necrosis. Extensive injury of the proximal tubules was observed. The lesions were more severe and higher drug concentrations were achieved in the kidneys of the q6h dosing group. The q24h dosing group experienced a more gradual onset of nephrotoxicity, which could be attributed to the lower kidney tissue drug concentrations (48.5 ± 17.4 μg/g versus 92.1 ± 18.1 μg/g of polymyxin B1, P = 0.04). Preferential accumulation of polymyxin B in the kidneys suggests that uptake to renal cells is a nonpassive process and q24h dosing was less nephrotoxic than q6h dosing.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Concentrations of the major components of polymyxin B (PB) in rat kidneys. Data are shown as means ± standard deviations. PB1, polymyxin B1; ile-PB1, isoleucine polymyxin B1; PB2, polymyxin B2; PB3, polymyxin B3.
Fig 2
Fig 2
Histological comparison of renal lesions. Shown are the renal cortical tissue and the outer stripe of the medulla of normal kidney (A and B), with q24h dosing (C and D), and with q6h dosing (E and F). Hematoxylin and eosin stain and ×200 magnification were used for all panels. For panels C and D, the q24h dosing was associated with focal tubular cell necrosis (arrows) in both locations, together with focal tubular cell cytoplasmic attenuation (open arrow). For panels E and F, the q6h dosing was associated with more severe changes in both locations, including tubular cell necrosis (arrows), extensive cytoplasmic attenuation (open arrow), and vacuolization (box).
Fig 3
Fig 3
Comparison of the onset of nephrotoxicity between the dosing groups.

References

    1. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. 2010. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568–1574 - PubMed
    1. Drusano GL, et al. 2007. Back to the future: using aminoglycosides again and how to dose them optimally. Clin. Infect. Dis. 45:753–760 - PubMed
    1. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. 2006. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin. Microbiol. Infect. 12:1227–1230 - PubMed
    1. Garnacho-Montero J, et al. 2003. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin. Infect. Dis. 36:1111–1118 - PubMed
    1. Garonzik SM, et al. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284–3294 - PMC - PubMed

Publication types

MeSH terms